Analysts Set Metagenomi, Inc. (NASDAQ:MGX) PT at $10.00

Shares of Metagenomi, Inc. (NASDAQ:MGX) have been assigned an average recommendation of “Moderate Buy” from the five analysts that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, three have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $10.00.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Metagenomi in a report on Monday, December 22nd.

Metagenomi Stock Performance

Shares of NASDAQ:MGX opened at $1.55 on Monday. The stock has a market capitalization of $58.20 million, a P/E ratio of -0.65 and a beta of 0.50. Metagenomi has a 1 year low of $1.23 and a 1 year high of $3.95. The stock has a 50-day simple moving average of $1.61 and a 200-day simple moving average of $1.94.

Institutional Investors Weigh In On Metagenomi

A number of large investors have recently modified their holdings of MGX. Vanguard Personalized Indexing Management LLC lifted its position in Metagenomi by 53.1% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 21,515 shares of the company’s stock worth $32,000 after acquiring an additional 7,458 shares in the last quarter. BNP Paribas Financial Markets boosted its stake in shares of Metagenomi by 1,840.0% in the third quarter. BNP Paribas Financial Markets now owns 15,171 shares of the company’s stock valued at $36,000 after purchasing an additional 14,389 shares during the period. Bank of America Corp DE grew its holdings in Metagenomi by 508.5% during the 3rd quarter. Bank of America Corp DE now owns 18,766 shares of the company’s stock valued at $44,000 after purchasing an additional 15,682 shares in the last quarter. Panagora Asset Management Inc. purchased a new stake in Metagenomi during the 4th quarter worth $53,000. Finally, Quadrature Capital Ltd acquired a new position in Metagenomi in the 4th quarter worth $55,000.

Metagenomi Company Profile

Metagenomi, Inc (NASDAQ: MGX) is a biotechnology company that specializes in the discovery and engineering of novel proteins and enzymes using metagenomics and CRISPR-based genome editing. The company’s proprietary platform integrates vast environmental DNA libraries with advanced machine learning and high-throughput screening to identify, optimize and commercialize enzymes for industrial, agricultural and pharmaceutical applications. By tapping into genetic diversity found in nature, Metagenomi aims to accelerate the development of tailored biocatalysts that improve process efficiency, reduce costs and support sustainability initiatives.

Metagenomi’s technology offerings include custom enzyme discovery services, protein engineering tools and licensing of optimized biocatalysts to partners across multiple sectors.